Cystic fibrosis
ReCode is aiming to advance its lead candidates for cystic fibrosis and primary ciliary dyskinesia (PCD).
Choosing to exercise its options with a group of research and development partners, the pharma giant will accelerate a promising new C.F. gene therapy.
The data showed that both experimental therapies restored function in the cystic fibrosis transmembrane conductance regulator gene.
“The recent progress of cystic fibrosis drugs has been amazing and, in my case, miraculous,” said Kelly Peters, who lives with cystic fibrosis. “The new drugs are not a cure, but they feel pretty close.”
PRESS RELEASES